AFLAC earnings date
AFLAC (AFL) Q3 2026 Earnings Report
DE:AFL Q3 2026 EPS Results
- Actual EPS
- EUR 2.20
- Consensus EPS
- EUR 1.62
- Beat/Miss
- Beat by +EUR 0.57
- One Year Ago EPS
- EUR 2.25
DE:AFL Q3 2026 Revenue Results
- Actual Revenue
- EUR 2.96B
- Expected Revenue
- EUR 3.72B
- Beat/Miss
- Missed by -EUR 766.55M
- YoY Revenue Growth
- -30.99%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
AFLAC's next earnings date is estimated for February 3, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive. Management reported solid adjusted earnings, strong capital and liquidity, favorable US growth, raised 2026 Japan and US profitability expectations, substantial shareholder returns, and additional reinsurance and investment opportunities. These strengths outweighed the quarterly Japan sales decline, lower adjusted book value, cybersecurity-related disruption and expenses, investment valuation charges, mixed investment income, and continued pressure in selected businesses.
Aflac continues to expect Aflac Japan sales to exceed 2025, with 2026 Japan benefit ratio slightly below the 60 to 63% range, expense ratio on the lower end of the 2023% range, and pretax profit margin of 35 to 38%; in the US, 2026 benefit ratio is expected to be below the 48 to 52% range, expense ratio in the middle of the 36 to 39% range, and pretax profit margin above the 17 to 20% range. Aflac Japan has ceded about 15% of total FSA reserves versus an internal risk limit of 30%, leaving very meaningful runway for further reinsurance transactions. The company expects the fourth quarter to be better than last year, including an extra week of productivity, and expects Tsumitasu to continue to play an important role in 2027.
- Strong Adjusted Earnings and ReturnsThird quarter adjusted earnings per diluted share were reported as $2.43 by Daniel Amos and $2.46 excluding foreign currency by Max Broden; Max stated that adjusted earnings per diluted share decreased 1.2% year over year to $2.46. Adjusted ROE was 17.8%, or 23.7% excluding foreign currency remeasurement, described as a significant spread to the company's cost of capital.
- Leadership Succession Plan AnnouncedEffective January 1, 2027, Shinsuke Morimoto will become president of Aflac Japan, Fred Samard will become president of Aflac US, Masatoshi Koide will become chairman of Aflac Japan, and Charles Lake will become chairman of Aflac International and executive adviser of Aflac Japan. Management described the changes as the result of a long-term, deliberate succession planning process.
- Japan Sales Expected to Exceed 2025Aflac Japan third-quarter sales declined 4% to ¥18.8 billion against a difficult comparison following the launch of Miraito Cancer Insurance, but sales increased 3% for the first nine months. Management continued to expect full-year Aflac Japan sales to exceed 2025.
- Japan Product Momentum and Distribution StrengthTsumitasu sales increased both year over year and sequentially, while Onshin Pallet medical insurance sales increased over the prior year. Miraito Cancer Insurance sales remained relatively strong, and management said Aflac Japan's agencies, alliance partners, and banks continue to provide broad distribution across different demographics and life stages.
- Solid Japan Persistency and Claims ExperienceJapan premium persistency was 92.9%, in line with expectations. Management cited favorable cancer-related hospitalization and mortality trends, leading to favorable actual-to-expected experience.
- Japan Guidance RaisedBased on a year-to-date benefit ratio of 58.8%, management now expects the 2026 Japan benefit ratio to be slightly below the 60 to 63% range and the expense ratio to be on the lower end of the 2023% range. The expected 2026 Japan pretax profit margin range was raised to 35 to 38%.
- US Sales and Premium GrowthAflac US third-quarter sales increased 3.5% year over year, net earned premiums increased 3.3%, and premium persistency was 79.7%, up 70 basis points year over year. The US pretax profit margin was 27.7%.
- Strong US Growth in Group PlatformsThe US group platform's earned premium increased 17%, group life and absence and disability increased 29%, dental and vision increased 55%, and voluntary benefits increased 7.5%. The three targeted platforms—group life, absence and disability, consumer markets, and dental and vision—generated 15% growth in the quarter.
- Dental and Vision Strategy Showing TractionDental and vision sales increased 67% in the quarter. Management said 90 cents of every dollar of dental products sold was also sold with a voluntary benefit product, indicating that the intended cross-selling strategy was working.
- US Profitability Guidance RaisedManagement expects the 2026 US benefit ratio to be below the 48 to 52% range, the expense ratio to be in the middle of the 36 to 39% range, and the US pretax profit margin to be above the 17 to 20% range.
- Reinsurance Transaction Released CapitalAflac Japan ceded approximately ¥500 billion of cancer insurance reserves on an FSA basis to Aflac Re Bermuda. The transaction increased total ceded Aflac Japan FSA reserves to approximately 15%, versus an internal risk limit of 30%, and management estimated that it would release approximately $1 billion of capital over time for redeployment.
- Further Reinsurance RunwayManagement said the company has meaningful runway to continue reinsurance transactions between Aflac Japan and Aflac Re Bermuda to improve the risk composition of Aflac Japan, enhance capital and liquidity, and improve group ROE. External reinsurance was also described as a significant opportunity with limited expected capital consumption and strong cash-capital generation.
- Attractive First-Sector Business OpportunityManagement said higher yen interest rates created an opportunity to significantly grow first-sector savings business, which offers extremely attractive new business IRRs and very attractive value of new business, especially after reinsurance. Tsumitasu represented approximately 20% of total Japan sales and was described as supporting customer-base expansion and concurrent sales of cancer and medical insurance.
- Investment Portfolio Repositioning Improved Future IncomeAflac repositioned $2.3 billion of Japanese government bonds in the quarter to take advantage of some of the highest interest rates in a generation. The trade was expected to improve future net investment income by over $30 million, while year-to-date portfolio management had added over $80 million of annual net investment income and reduced the risk of future FSA impairments.
- Strong Capital, Liquidity, and Shareholder ReturnsUnencumbered liquidity was $2.7 billion, or $1.7 billion above the $1 billion minimum balance. Adjusted leverage was 22.6%, within the 20% to 25% target range. Estimated regulatory ESR was 225%, or 238% including the undertaking-specific parameter, and combined RBC was slightly above 575%. The company repurchased $804 million of stock and paid $305 million of dividends in the quarter, while returning $1.1 billion to shareholders in total.
- Long Dividend Growth RecordAflac marked 44 consecutive years of dividend increases in 2026 and stated that it remains committed to tactical capital deployment, prudent liquidity management, and supporting policyholders.
- Corporate and Other Earnings GrowthCorporate and other adjusted revenues increased 5% to $360 million, while pretax adjusted earnings increased to $72 million from $69 million, primarily driven by $91 million of remeasurement gains from unlocking actuarial assumptions and new reinsurance transactions.
DE:AFL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 03, 2027 | 2027 (Q4) | 1.60- | 1.42 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 1.622.20 | 2.25 | -2.41% (-0.05) | |
| Aug 06, 2026 | 2026 (Q2) | 1.591.58 | 1.61 | -1.69% (-0.03) | |
| Apr 29, 2026 | 2026 (Q1) | 1.621.58 | 1.5 | 5.42% (+0.08) | |
| Feb 04, 2026 | 2025 (Q4) | 1.542.39 | 1.41 | 69.23% (+0.98) | |
| Feb 04, 2026 | 2026 (Q4) | 1.531.42 | 1.41 | 0.64% (+0.01) | |
| Nov 04, 2025 | 2025 (Q3) | 1.602.25 | 1.95 | 15.28% (+0.30) | |
| Aug 05, 2025 | 2025 (Q2) | 1.541.61 | 1.65 | -2.73% (-0.05) | |
| Apr 30, 2025 | 2025 (Q1) | 1.511.50 | 1.5 | 0.00% (+0.00) | |
| Feb 05, 2025 | 2024 (Q4) | 1.471.41 | 1.16 | 21.88% (+0.25) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


